RedHill Receives FDA Approval for H. Pylori Gastric Drug
H. pylori is a type of drug-resistant gastric bacteria linked with increased risks of developing ulcers and stomach cancer
Tzally Greenberg | 11:47 05.11.2019
Nasdaq and Tel Aviv-listed pharmaceutical company RedHill Biopharma Ltd. has received U.S. Food and Drug Administration (FDA) clearance for its new pill TALICIA, which provides antibiotic treatment of Helicobacter pylori gastric infections, the company announced in a Monday filing. H. pylori is a type of gastric bacteria linked with increased risks of developing ulcers and stomach cancer. In December, RedHill announced a successful clinical trial in which TALICIA, composed of the antibiotics rifabutin and amoxicillin, managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care.